JP2008502683A5 - - Google Patents

Download PDF

Info

Publication number
JP2008502683A5
JP2008502683A5 JP2007516542A JP2007516542A JP2008502683A5 JP 2008502683 A5 JP2008502683 A5 JP 2008502683A5 JP 2007516542 A JP2007516542 A JP 2007516542A JP 2007516542 A JP2007516542 A JP 2007516542A JP 2008502683 A5 JP2008502683 A5 JP 2008502683A5
Authority
JP
Japan
Prior art keywords
alkyl
hydrogen
optionally substituted
nitrogen
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007516542A
Other languages
English (en)
Japanese (ja)
Other versions
JP5000492B2 (ja
JP2008502683A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/019901 external-priority patent/WO2005123668A1/en
Publication of JP2008502683A publication Critical patent/JP2008502683A/ja
Publication of JP2008502683A5 publication Critical patent/JP2008502683A5/ja
Application granted granted Critical
Publication of JP5000492B2 publication Critical patent/JP5000492B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2007516542A 2004-06-14 2005-06-08 グルカゴン受容体拮抗物質及びその調製並びに治療的使用 Expired - Lifetime JP5000492B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57936204P 2004-06-14 2004-06-14
US60/579,362 2004-06-14
PCT/US2005/019901 WO2005123668A1 (en) 2004-06-14 2005-06-08 Glucagon receptor antagonists, preparation and therapeutic uses

Publications (3)

Publication Number Publication Date
JP2008502683A JP2008502683A (ja) 2008-01-31
JP2008502683A5 true JP2008502683A5 (enExample) 2012-05-10
JP5000492B2 JP5000492B2 (ja) 2012-08-15

Family

ID=35219490

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007516542A Expired - Lifetime JP5000492B2 (ja) 2004-06-14 2005-06-08 グルカゴン受容体拮抗物質及びその調製並びに治療的使用

Country Status (28)

Country Link
US (3) US7816557B2 (enExample)
EP (2) EP2159221A1 (enExample)
JP (1) JP5000492B2 (enExample)
KR (1) KR100835496B1 (enExample)
CN (1) CN1968921B (enExample)
AT (1) ATE455756T1 (enExample)
AU (2) AU2005254950B2 (enExample)
BR (1) BRPI0512058A (enExample)
CA (1) CA2569459C (enExample)
CY (1) CY1109787T1 (enExample)
DE (1) DE602005019043D1 (enExample)
DK (1) DK1758853T3 (enExample)
EA (1) EA013003B1 (enExample)
EC (1) ECSP067082A (enExample)
ES (1) ES2337596T3 (enExample)
HR (1) HRP20100148T1 (enExample)
IL (1) IL179599A (enExample)
MA (1) MA28706B1 (enExample)
MX (1) MXPA06014426A (enExample)
NO (1) NO341028B1 (enExample)
NZ (1) NZ551015A (enExample)
PL (1) PL1758853T3 (enExample)
PT (1) PT1758853E (enExample)
RS (1) RS51202B (enExample)
SI (1) SI1758853T1 (enExample)
UA (1) UA86621C2 (enExample)
WO (1) WO2005123668A1 (enExample)
ZA (1) ZA200610298B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1758853T3 (da) * 2004-06-14 2010-04-06 Lilly Co Eli Glucagon-receptorantagonister, fremstilling og terapeutiske anvendelser
US7524870B2 (en) * 2004-12-03 2009-04-28 Hoffmann-La Roche Inc. Biaryloxymethylarenecarboxylic acids as glycogen synthase activators
ATE445609T1 (de) * 2005-02-11 2009-10-15 Lilly Co Eli Substituierte thiophenderivate als glucagonrezeptorantagonisten, herstellung und therapeutische anwendungen
CA2600159A1 (en) 2005-03-21 2006-09-28 Merck & Co., Inc. Substituted aryl and heteroaryl derivatives, compositions containing such compounds and methods of use
WO2007120270A2 (en) * 2005-11-22 2007-10-25 Eli Lilly And Company Glucagon receptor antagonists, preparation and therapeutic uses
EP2019585A2 (en) 2006-05-16 2009-02-04 Merck & Co., Inc. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
KR20170085615A (ko) 2007-02-09 2017-07-24 메타베이시스 테라퓨틱스, 인크. 글루카곤 수용체의 길항제
EP2799428B1 (en) 2008-08-13 2016-11-16 Metabasis Therapeutics, Inc. Glucagon antagonists
WO2010098948A1 (en) * 2009-02-13 2010-09-02 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containin such compounds and methods of use
US8039495B2 (en) * 2009-11-16 2011-10-18 Hoffman-La Roche Inc. Biphenyl carboxylic acids and bioisosteres as glycogen synthase activators
JP5694561B2 (ja) 2010-12-23 2015-04-01 ファイザー・インク グルカゴン受容体モジュレーター
WO2012107850A1 (en) 2011-02-08 2012-08-16 Pfizer Inc. Glucagon receptor modulator
KR20140023441A (ko) 2011-07-22 2014-02-26 화이자 인코포레이티드 퀴놀린일 글루카곤 수용체 조절제
EP2785740A1 (en) 2011-12-02 2014-10-08 Eli Lilly and Company Anti-glucagon antibodies and uses thereof
US20140210770A1 (en) * 2012-10-04 2014-07-31 Corning Incorporated Pressure sensing touch systems and methods
TW201427658A (zh) * 2012-12-10 2014-07-16 Merck Sharp & Dohme 藉由投予升糖素受體拮抗劑及膽固醇吸收抑制劑治療糖尿病之方法
WO2015066252A1 (en) 2013-11-04 2015-05-07 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions thereof, and methods of use
EP3154956A4 (en) 2014-06-12 2018-01-17 Ligand Pharmaceuticals, Inc. Glucagon antagonists
CN108290840A (zh) 2015-12-01 2018-07-17 巴斯夫欧洲公司 作为杀真菌剂的吡啶化合物
WO2017093120A1 (en) 2015-12-01 2017-06-08 Basf Se Pyridine compounds as fungicides
AU2018278714B2 (en) 2017-05-30 2022-06-02 Basf Se Pyridine and pyrazine compounds
CN111954560A (zh) 2018-02-13 2020-11-17 配体药物公司 胰高血糖素受体拮抗剂
CN111184706B (zh) * 2020-03-05 2020-11-17 牡丹江医学院 一种防治胆囊炎的活性药物及其用途
KR102606541B1 (ko) * 2021-04-23 2023-11-29 가천대학교 산학협력단 바이페닐설폰아마이드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 글루카곤 수용체 활성 관련 질환의 예방 또는 치료용 약학적 조성물

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4973731A (en) 1987-04-23 1990-11-27 Riker Laboratories, Inc. Di-t-butylphenyl alkyl and benzyl ether nitriles
GB9420557D0 (en) 1994-10-12 1994-11-30 Zeneca Ltd Aromatic compounds
JP2003504301A (ja) * 1998-04-01 2003-02-04 ブリストル−マイヤーズ スクイブ ファーマ カンパニー インテグリンアンタゴニスト
WO2000069810A1 (en) * 1999-05-17 2000-11-23 Novo Nordisk A/S Glucagon antagonists/inverse agonists
CN1437581A (zh) * 2000-06-23 2003-08-20 诺沃挪第克公司 胰高血糖素拮抗剂/反向激动剂
US6706744B2 (en) 2000-11-17 2004-03-16 Novo Nordisk A/S Glucagon antagonists/inverse agonists
EP1463715A1 (en) * 2001-12-03 2004-10-06 Novo Nordisk A/S Novel glucagon antagonists
WO2004002480A1 (en) * 2002-06-27 2004-01-08 Novo Nordisk A/S Novel glucagon antagonists/inverse agonists
AU2003291959A1 (en) 2002-12-20 2004-07-14 Novo Nordisk A/S Novel glucagon antagonists
WO2005102067A1 (en) 2004-04-26 2005-11-03 Ipn Ip B.V. Packaged flowable ice product, such as a milk shake
ES2428538T3 (es) 2004-05-28 2013-11-08 Eli Lilly And Company Antagonistas del receptor de glucagón, preparación y usos terapéuticos
DK1758853T3 (da) * 2004-06-14 2010-04-06 Lilly Co Eli Glucagon-receptorantagonister, fremstilling og terapeutiske anvendelser
ATE445609T1 (de) * 2005-02-11 2009-10-15 Lilly Co Eli Substituierte thiophenderivate als glucagonrezeptorantagonisten, herstellung und therapeutische anwendungen
CA2600159A1 (en) 2005-03-21 2006-09-28 Merck & Co., Inc. Substituted aryl and heteroaryl derivatives, compositions containing such compounds and methods of use
DK1951658T3 (da) 2005-11-17 2012-10-15 Lilly Co Eli Glucagonreceptorantagonister, fremstilling og terapeutiske anvendelser
CA2629348C (en) 2005-11-17 2013-08-13 Eli Lilly And Company Glucagon receptor antagonists, preparation and therapeutic uses
BRPI0618484A2 (pt) 2005-11-18 2011-08-30 Lilly Co Eli composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos para inibir o receptor de glucagon em um mamìfero, para reduzir seletivamente o nìvel glicêmico em um mamìfero e para tratar diabete tipo 2, e, uso de um composto ou um sal do mesmo
WO2007120270A2 (en) 2005-11-22 2007-10-25 Eli Lilly And Company Glucagon receptor antagonists, preparation and therapeutic uses
US7807702B2 (en) 2005-11-23 2010-10-05 Eli Lilly And Company Substituted thiophene carboxylic amide glucagon receptor antagonists, preparation and therapeutic uses

Similar Documents

Publication Publication Date Title
JP2008502683A5 (enExample)
JP2008530102A5 (enExample)
JP2013504593A5 (enExample)
AR066120A1 (es) Derivados de pirimidinona y sus metodos de uso
PH12012501773A1 (en) Arylethynyl derivatives
JP2012532135A5 (enExample)
JP2011519854A5 (enExample)
JP2009533410A5 (enExample)
EA200602058A1 (ru) Производные адамантилпирролидин-2-она в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы
RU2009105669A (ru) Способ получения 3-замещенных 2-амино-5-галогенбензамидов
JP2009511490A5 (enExample)
JP2009519903A5 (enExample)
RU2014128826A (ru) Дисоли малоновой кислоты и способ получения малонилдигалогенидов
WO2009156861A8 (en) Substituted pyrimidone derivatives
HRP20100148T1 (hr) Antagonisti glukagonskog receptora, priprema i terapijska primjena
JP2011511810A5 (enExample)
JP2012504608A5 (enExample)
JP2013542213A5 (enExample)
MX360667B (es) Derivados de etinilo como moduladores alostericos del receptor de glutamato metabotropico del subtipo 5 (mglur5).
JP2015530408A5 (enExample)
JP2006508979A5 (enExample)
CA2415532A1 (en) Novel 4-phenyl substituted tetrahydroisoquinolines therapeutic use thereof
JP2006509842A5 (enExample)
JP2008540454A5 (enExample)
JP2014521609A5 (enExample)